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REVIEW
Coenzyme Q10 and the exclusive club of diseases that show a limited response to 
treatment
Nadia Turton, Nathan Bowers, Sam Khajeh, Iain P Hargreaves and Robert A Heaton
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool UK
ABSTRACT
Introduction: Coenzyme Q10 (CoQ10) is a ubiquitous organic molecule with a significant role in the 
mitochondrial electron transport chain (ETC). As a result of its role in such an important biological 
process, CoQ10 deficiency has been implicated in the pathogenesis of numerous diseases such as 
Parkinson’s disease (PD) and multiple sclerosis (MS). This has led to multiple attempts to use CoQ10 
supplementation as a treatment or pre-treatment with varying degrees of success.
Areas covered: The present review will identify evidence of mitochondrial dysfunction in MS, PD and 
mitochondrial ETC disorders. In addition, the inability of Co10 supplementation to elicit significant 
clinical outcome in these disorders and possible flaws in these studies will be discussed. The databases 
utilized for this review were the Web of science and PubMed, with inclusive dates (1957–2021).
Expert opinion: A lack of improved neurological outcome in these disorders post treatment with CoQ10 
may be attributable to the limited ability of CoQ10 to cross the blood–brain barrier. Thus, CoQ10 
alternatives should also be considered. Other factors including time of disease diagnosis, dosage, 
administration, and duration of CoQ10 therapy may have a significant influence on the efficacy of this 
treatment.
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Coenzyme Q10 (CoQ10) is the dominant form of ubiquinone 
found in humans and can be found in almost all cellular 
membranes [1]. This lipid-soluble molecule is made up of 
a benzoquinone moiety, with a 10-subunit polyisoprenoid 
lipid tail [2] (Figure 1). The central benzoquinone ring includes 
two redox active sites, essential for its cellular function, 
whereas the polyisoprenoid tail is responsible for the correct 
positioning in a variety of membranes [2].
The synthesis of CoQ10 can be divided into three distinct 
steps. Firstly, the synthesis of the benzoquinone ring from 
4-hydroxybenzoate, followed by the synthesis of the polyiso-
prenoid tail from acetyl-coenzyme A (CoA) utilizing the meva-
lonate pathway and finally, the condensation of the two 
structures to form CoQ10 [3]. The condensation step in CoQ10 
synthesis takes place within the mitochondria and has been 
suggested to be the rate limiting step in the CoQ10 biosyn-
thetic pathway [4].
CoQ10 plays a significant role in a number of biochemical 
pathways within the mitochondrion [2]. However, CoQ10’s 
principal function is as an electron carrier, exchanging elec-
trons derived from both complex I and II and transferring 
them to complex III facilitating electron transfer in the mito-
chondrial electron transport chain (ETC; Figure 2). In addition, 
CoQ10 also functions as an essential lipid-soluble antioxidant 
within the cell, and because of CoQ10’s ubiquitous nature it 
not only protects the mitochondrial membrane from free 
radical induced oxidation, but also that of other organelle 
membranes together with the plasma membrane [3]. 
Additionally, CoQ10 is also involved in the regeneration of 
other cellular antioxidants such as vitamin C and E [5]. In 
a recent study by Heaton, Heales [6] evidence showed that 
cellular CoQ10 concentration can even influence the lysosomal 
lumen pH, although the mechanism by which this occurs has 
yet to be elucidated.
In view of coQ10’s functional role, CoQ10 has been supple-
mented in response to three disorders of the central nervous 
system (CNS), of which they have displayed evidence of mito-
chondrial dysfunction and oxidative stress [3,7,8]. These dis-
orders include multiple sclerosis (MS), mitochondrial electron 
transport chain (ETC) disorders and Parkinson’s disease (PD). 
The present review will evaluate the inability of Co10 supple-
mentation to elicit significant clinical outcome in these disor-
ders and possible flaws in these studies will be discussed.
1.1. CoQ10 Deficiency
CoQ10 deficiencies can be divided into two categories, primary 
and secondary deficiencies [2]. Primary COQ10 deficiencies are 
caused by mutations in the genes directly involved in the 
biosynthesis of CoQ10 [9,10]; whereas secondary deficiencies 
have been associated with mutations in genes that are indir-
ectly related to CoQ10 biosynthesis, or to other non-genetic 
factors [11].
Due to the plethora of different biochemical functions of 
COQ10, the clinical consequences resulting from aCoQ10 defi-
ciency can have a wide spectrum of presentations. In 
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particular, a CoQ10 deficiency results in the impairment of the 
METC, leading to a reduced cellular ATP production [12]. 
Primary CoQ10 deficiencies are most often reported in tissues 
with high energy demand such as the CNS [12]. The clinical 
presentation and severity of primary CoQ10 deficiencies can 
vary drastically ranging from a mild clinical phenotype to 
a severe infantile presentation which can often be fatal [13].
Secondary CoQ10 deficiency typically presents in diseases 
such as mitochondrial myopathies [14,15], cardiovascular dis-
ease [16], type II diabetes [17], chronic kidney disease [18], 
liver disease and critical illness [19]. In common with a primary 
CoQ10 deficiency the deficit in CoQ10 contributes to disease 
pathophysiology in these disorders by impairing energy meta-
bolism and compromising cellular antioxidant status. As dis-
cussed previously, a secondary CoQ10 deficiency can be 
caused by non-genetic factors such as the pharmacological 
agents, statins [20]. Statins reduce the circulatory levels of low- 
density lipoprotein (LDL) through the competitive inhibition of 
the enzyme, 3-hydroxy-3-methyl-glutaryl-coenzyme 
A reductase (HMG-CoA reductase) (Figure 3) which serves as 
a major regulatory role in both cholesterol and CoQ10 bio-
synthesis [21]. A number of studies have reported reduced 
CoQ10 status following statin treatment [21]. However, the 
majority of these studies assessed endogenous CoQ10 status 
in plasma/serum, which may only reflect the decrease in LDL, 
as LDL is the principal carrier of CoQ10 in the circulation [3]. 
Only a small number of studies have directly measured CoQ10 
muscle status which is thought to be a more accurate reflec-
tion of endogenous CoQ10 status [22].
2. Multiple sclerosis
MS is a chronic inflammatory disease of the CNS and currently 
the most common cause of non-traumatic neurological dis-
ability in young adults [23]. While the etiology and pathogen-
esis of MS still remain to be fully elucidated, research suggests 
that genetic predisposition and environmental factors trigger 
the permeation of myelin-specific autoreactive lymphocytes 
into the CNS, an important causative factor for MS [24–26]. 
The entry of these lymphocytes into the CNS results in multi-
focal demyelination, neural and axonal damage, oligodendro-
cyte loss, blood–brain barrier (BBB) breakdown and oxidative 
stress [23,27–29]. The clinical presentation of MS includes 
optic neuritis, diplopia, fatigue, paralysis, paresthesias and 
cognitive dysfunction [30]. MS can be categorized into four 
disease states including relapsing-remitting multiple sclerosis 
(RRMS), secondary progressive multiple sclerosis (SPSM), pri-
mary progressive multiple sclerosis (PPMS), and progressive- 
relapsing multiple sclerosis (RPMS) [31,32]. The majority of MS 
patients experience RRMS, during which an episode of neuro-
logical impairment is followed by partial or complete remis-
sion [33,34].
Figure 1. Chemical structure of coenzyme Q10 (CoQ10) N = 10.
Figure 2. Diagram of electron transport chain (ETC) and ATP synthase illustrating the pumping of H+ ions into the intermembrane space, and how CoQ10 augments 
the passage of electrons. Created using BioRender.com (template provided by Biorender).
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2.1. Mitochondrial dysfunction and oxidative stress in 
MS
It is becoming increasingly apparent that oxidative stress 
accompanies neuro-inflammation observed in MS, which can 
result in secondary mitochondrial dysfunction [35]. This injur-
ious effect upon the mitochondria can result in further reac-
tive oxygen species (ROS) production continuing the cycle of 
free radical generation, eventually resulting in decreased neu-
ronal ATP production [36,37]. These factors ultimately lead to 
activation of apoptosis and progressive axon degeneration, 
which can extenuate to the neuronal body and dendrites 
and eventually the presynaptic and postsynaptic neurons 
[38]. Mitochondrial dysfunction has been associated with the 
disease pathogenesis of MS, since deficiencies in ETC complex 
IV, citrate synthase (mitochondrial matrix marker) and complex 
I (NADH dehydrogenase: ubiquinone reductase) activities have 
been detected in the active lesions of postmortem brain sam-
ples taken from chronic MS patients [39]. Similarly, Sadeghian 
et al. [40] reported that the activity of ETC complex I was 
selectively compromised in the spinal tissue in a mouse 
model of the disease (experimental autoimmune encephalo-
myelitis; EAE), together with an increase in astrocytic phos-
phofructokinase 2 (PFK2) expression and a shift from oxidative 
to glycolytic metabolism. These findings accompanied depo-




Figure 3. Schematic diagram of the CoQ10 biosynthetic pathway, demonstrating how pharmacological inhibition, such as statin therapy may also influence the 
synthesis of CoQ10. Adapted from Hargreaves, Duncan [20].
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thus, correlating with neurological deficits. Evidence of mito-
chondrial dysfunction is relatively unexplored in other tissues; 
however, Hargreaves et al. [41] reported statistically significant 
alterations to ETC complex I and complex II/III (succinate: 
ubiquinone reductase) activities at the pre-symptomatic and 
asymptomatic stages in spinal cord, jaw muscle and liver 
tissues of EAE mouse models of MS. ETC complex I has been 
reported to be the main site of ROS production in the ETC [42]; 
thus, increased levels of oxidative stress reported in MS 
patients [43] may be attributable to a decrease observed in 
complex I activity [39,40]. Additionally, lymphocytes isolated 
from MS patients were found to have a significant reduction in 
mitochondrial membrane potential compared to healthy con-
trols [44]. The differences in mitochondrial function identified 
in this study were proportional to the degree of MS severity, 
again suggesting mitochondrial dysfunction may contribute to 
the pathogenesis of disease progression in MS and is not 
limited to the CNS.
2.2. CoQ10 limitations in MS
In view of the evidence of mitochondrial dysfunction and 
oxidative stress reported in the pre-symptomatic and sympto-
matic stages of MS, the ETC electron carrier and lipid-soluble 
antioxidant, CoQ10 may be considered as a potential adjunct 
therapy to control disease progression [15,45]. However, 
although proven to be beneficial in some cases, several stu-
dies have suggested that CoQ10 still has some therapeutic 
limitations in the treatment of MS and this will be outlined 
in the following section.
Sanoobar et al. [46] demonstrated that CoQ10 supplemen-
tation had no effect on the activity of the antioxidant enzyme, 
glutathione peroxidase (GPx) in RRMS patients. In this study, 
fasting blood samples were taken from 45 subjects with MS 
before and after a 12-week intervention with CoQ10 and 
a placebo control. However, despite an increase in superoxide 
dismutase activity (SOD), a decrease in malondialdehyde 
(MDA; marker of lipid peroxidation) levels and reduced total 
antioxidant capacity (TAC) levels detected in the CoQ10 treated 
MS patient group, no significant difference in GPx activity was 
identified between the control and treated groups. Previously, 
reduced levels of peripheral GPx activity have been reported 
in MS patients compared to healthy controls [47]. It has been 
suggested that GPx may make more of a contribution than the 
antioxidant enzyme, catalase in detoxifying cellular hydrogen 
peroxide [48]. Thus, in view of the susceptibility of the CNS to 
ROS induced oxidative damage, CoQ10 supplementation does 
not appear to have the capacity to up-regulate the activity of 
the vital antioxidant enzyme, GPx in MS, which may therefore 
limit the ability of CoQ10 to delay disease progression [46].
One potential therapeutic mechanism of CoQ10 is its ability 
to adjust the immune response [49]. Inflammation is a key 
contributor to axonal injury in MS, of which anti-inflammatory 
cytokines are decreased and pro-inflammatory cytokines are 
increased in the CSF [50,51]. A study by Sanoobar et al. [7] 
reported that CoQ10 supplementation for 12 weeks (500 mg/ 
day) did not alter levels of anti-inflammatory cytokines trans-
forming growth factor-β (TGF- β) and interleukin (IL)-4 in the 
serum of MS patients compared to the placebo group. 
Similarly, in an EAE C57BL/6 female adult mouse model 
study of MS, Soleimani et al. [52] observed no alterations in 
the levels of IL-4 in the CoQ10 treated group compared to the 
untreated group. TGF- β can suppress T-cell proliferation, 
macrophage activity and cytotoxic lymphocyte maturation 
[53]. Similarly, IL-4 inhibits the ability of macrophages to pro-
duce TNF-α, IL-1 and IL-6 [54,55]. Both of which have demon-
strated protective properties in EAE models [56,57]. However, 
CoQ10 may utilize its anti-inflammatory effects via the inhibi-
tion of pro-inflammatory cytokines, as opposed to increasing 
anti-inflammatory cytokines [7,52]. On the contrary, 12-week 
CoQ10 (200 mg/day) supplementation in RRMS patients trea-
ted with interferon beta1a 44 μg (IFN-β1a) demonstrated 
higher levels of IL-4 in the peripheral blood [58]. However, at 
present we cannot exclude the possibility that the increase in 
circulatory IL-4 was the result of IFN-β1a treatment rather than 
that of CoQ10. The studies discussed also required patient 
`follow up reports` that exceeded a 3-month intervention to 
identify meaningful changes over longer periods of time. 
Additionally, in view of the fact that MS is an inflammatory 
disease of the CNS, supplementary markers of MS severity 
should be included e.g magnetic resonance imaging data 
allow an assessment of the effect of CoQ10 supplementation 
on cerebral function.
Depression and fatigue are common symptoms of MS [59], 
and therefore, a randomized, double-blinded, placebo- 
controlled trial was undertaken to assess the effect of 
a CoQ10 supplementation (500 mg/day) on MS-related fatigue 
over a 12 week period [60]. In the study fatigue symptoms 
were measured using a fatigue severity scale (FSS). In the 
CoQ10 (500 mg/day) treated patient group a significant 
decrease in FSS was observed. Similarly, previous studies 
have observed improved fatigue sensation and physical per-
formance during fatigue-inducing workload trials at high-dose 
CoQ10 (300 mg/day) supplementation [61]. However, these 
levels of CoQ10 may be higher than that achievable with 
current oral CoQ10 formulation and lower doses of CoQ10 
(100 mg/day) have been shown to have no effect on fatigue 
during physical workload trials in healthy volunteers, which 
may translate into the effects of fatigue in MS patients [61]. 
Furthermore, it should also be considered that larger and 
long-term follow-up studies are required to confirm the anti- 
fatigue effects of CoQ10 in MS as well as developing more 
accurate methods of quantifying fatigue severity in MS follow-
ing CoQ10 supplementation. However, it should be noted that 
the etiology of MS-related fatigue is unknown and may be 
multifactorial and therefore may require more than one can-
didate therapy
3. Parkinson’s disease
PD is a neurodegenerative disorder that is pathologically char-
acterized by Lewy body formation and striatal dopamine 
depletion in the Substantia Nigra [8]. Abnormal accumulation 
of ROS in the neuronal cells of PD patients leads to a reduction 
in the antioxidant, glutathione. As a result, increased oxidative 
stress leads to mitochondrial respiratory chain dysfunction, the 
release of pro-apoptotic mitochondrial proteins and ulti-
mately, cell death [62]. As well as CoQ10’s role in the METC 
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(Figure 2), reduced CoQ10 is also an important antioxidant, 
protecting the membrane and lipoproteins from ROS [63]. 
Consequently, the therapeutic efficacy of CoQ10 in the treat-
ment of PD has been tested in numerous studies. The follow-
ing section evaluates the results obtained from some of the 
key trials that have been conducted, as well as discussing the 
potential future applications of CoQ10 in the treatment of PD.
3.1. CoQ10 limitation in PD
Results obtained from a phase II trial indicated that the pro-
gression of early-stage PD could be stabilized using oral CoQ10 
supplementation [64]. In this trial, patients were randomly 
assigned to a placebo group or CoQ10 treatment at dosages 
of 300, 600, or 1200 mg/d. Disease progression was then 
measured at one, four, eight, twelve and sixteen months 
using the Unified Parkinson’s Disease Rating Scale (UPDRS). 
This scale measures the mental and motor capacity of 
patients, as well as their ability to complete daily living activ-
ities and in doing so considers the various clinical features of 
PD. After eight months, the mean total UPDRS score of 
patients receiving 300 mg/d and 600 mg/d dosages was simi-
lar, but importantly, lower than that of the placebo group, 
suggesting that CoQ10 was effective in slowing disease pro-
gression. However, the UPDRS scores of the 1200 mg/d group 
were not significantly lower than both aforementioned 
groups, indicating that there is a dosage threshold required 
for maximum drug efficacy. Following these promising find-
ings, a phase III clinical trial involving 600 patients was con-
ducted using largely the same method [65]. In this trial, 
treated patients received CoQ10 dosages of 1200 mg/d or 
2400 mg/d. Despite 1200 mg/d being the highest dosage 
used in the previous study, the mean change in UPDRS score 
of treated patients was not significantly lower than that of the 
placebo group after 16 months. The researchers therefore 
concluded that CoQ10 showed no benefit and should not be 
used in the treatment of early-stage PD.
CoQ10 was unable to stabilize PD progression in the study 
described by Beal, Oakes [65], but further assessment of this 
potential treatment is not futile. Half of dopaminergic neurons 
within the substantia nigra of PD patients are damaged before 
clinical diagnosis [66]. As the average age of participants in 
this study was 65 years old, it is possible that the neurones of 
these patients were already significantly damaged prior to 
treatment with CoQ10, meaning its neuroprotective effects 
would be limited [67]. The answer to improving its therapeutic 
efficacy could therefore lie in using novel methods to diag-
nose the disease earlier. In addition, the loss of glutathione 
during presymptomatic Parkinson’s disease pathogenesis 
implies that supplementary antioxidants, such as CoQ10, 
could be advantageous in its treatment [68].
In both of the trials described, the studied populations 
consisted of a broad range of sporadic PD patients, this 
means their contrasting findings could have been the result 
of diverse gene mutations within their respective populations. 
A number of mutant genes have been linked to familial PD 
[69], for example, a mutation to the PINK1 gene prevents 
PINK1 from transferring electrons between complex 1 and 
CoQ10 in the MECT [70]. This mutation would significantly 
reduce the effectiveness of CoQ10 supplementation on disease 
progression, however, screening for it did not occur during 
patient selection, meaning the reported null effects of CoQ10 
in PD may have been skewed. The capacity of CoQ10 to reduce 
oxidative stress could still prove beneficial in treating patients 
suffering from other forms of the disease and should be 
investigated further. Both studies reported an increase in 
mean CoQ10 plasma levels from baseline to the last assess-
ment; however, as previously discussed, this is not an entirely 
accurate way to estimate tissue CoQ10 concentrations. In addi-
tion, neuronal cells have yet another limiting factor in the BBB 
permeability restricting the passage of CoQ10 into the cells 
[71]. Whilst creating compounds that can penetrate the BBB 
still proves difficult to this day, CoQ10 analogues that have 
better water solubility have been produced. Studies by 
Muthukumaran, Leahy [72] and Sikorska, Lanthier [73] have 
shown that water-soluble Ubisol-Q10 can stabilize the pro-
gression of PD in animal models; however, the positive results 
obtained from Sikorska, Lanthier [73] are caveated by reports 
that treatment disruption resulted in continued neuronal 
degradation. Analogues of CoQ10 which possess improved 
mitochondrial membrane penetration have also been pro-
duced [74]. MitoQ consists of CoQ10 bound to triphenyl alkyl 
phosphonium cations, the cations interact with negative mito-
chondrial membranes and in doing so improve CoQ10 uptake 
[75]. The therapeutic efficacy of MitoQ was tested in a study 
conducted by Snow, Rolfe [67] where treated patients were 
given 40 mg or 80 mg dosages of the compound each day for 
16 months. Whilst the mean UPDRS score of treated patients 
did not significantly differ from that of the placebo group, it is 
possible that late diagnosis of the disease, as well as struggles 
in getting the compound to cross the BBB hindered the 
results. If the above-mentioned obstacles can be overcome, 
water-soluble analogues of CoQ10 could still prove beneficial 
in treating PD. Proposals suggested by Park, Park [76] indicate 
that the answer to the BBB conundrum is continuous CoQ10 in 
traditional delivery. In their study, PD was induced in rat 
models using 6-hydroxydopamine. They were then injected 
with various dosages of CoQ10 solution, and their neurode-
generation measured. Measurements used in this study 
included behavioral and dopaminergic evaluation, as well as 
neurogenesis, angiogenesis and neuroinflammation analysis. 
Compared to the placebo group, models treated with high 
dosage CoQ10 solution showed significant improvements in 
every parameter. These results suggest that convection- 
enhanced delivery could improve CoQ10 therapeutic efficacy 
and therefore provide the basis for more research into what 
seems a promising avenue for PD treatment.
4. Mitochondrial electron transport chain disorders
The clinical heterogeneity and unpredictable nature of ETC 
disorders have not been conducive to the development of 
effective therapeutic strategies for these diseases. Treatment 
of these disorders is extremely challenging with no cure as yet 
in sight. Most patients with ETC disorders are afforded symp-
tomatic treatment to manage the various clinical presenta-
tions of the disease. Treatment can also involve therapy 
aimed at enhancing ETC function as well as reducing 
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increased ROS generation typically associated with ETC impair-
ment. In light of the prospect that supplementation with 
CoQ10 may increase the efficiency of electron transfer through 
the ETC in patients with disorders of the ETC, CoQ10 supple-
mentation is one of the regular therapeutic strategies used in 
specialist clinical centers [3]. However, at present there is 
a paucity of high-level evidence supporting the use of CoQ10 
in the treatment of patients with ETC disorders. However, 
a number of case studies have reported evidence of an 
increase in strength, accelerated post exercise recovery and 
an improvement in oxygen consumption in patients following 
CoQ10 supplementation [77]. The most consistent finding, 
however, following Co10 therapy appears to be at the 
biochemical level, with a decrease in plasma lactate levels 
being reported following supplementation [78].
4.1. CoQ10 limitations in ETC disorders
Presently, only a limited number of clinical trials have assessed 
the efficacy of CoQ10 as a treatment for mitochondrial disease 
(Table 1). The results of these studies have demonstrated no 
overall clinical benefit and mostly included patients with ETC 
disorders with variable clinical phenotypes and genotypes. 
This makes it difficult to draw definite conclusions on the 
responsiveness of COQ10 therapy on particular patient 
groups. Although no benefit in any of the outcomes was 
observed in two trials [79] evidence of improvement in muscle 
strength [80] and following exercise, a decrease in plasma 
lactate levels was reported [81] was reported. It has been 
suggested that the duration of the study and the dose of 
COQ10 administrated are both factors that may compromise 
the therapeutic efficacy of CoQ10 in clinical trials [82,83]. The 
lack of clinical trials that have assessed the effectiveness of 
CoQ10 for the treatment of mitochondrial disease can be 
attributed to the difficulty in recruiting a sufficient number 
of patients and the relatively high cost of conducting the trials 
themselves. Furthermore, the reasons for the refractory nature 
of the neurological sequelae associated with ETC dysfunction 
to CoQ10 supplementation may be a consequence of the 
relatively poor ability of CoQ10 to cross the BBB. Animal 
studies have suggested that CoQ10 supplementation can be 
transported across the BBB [A, B] (whats A and B). However, it 
is yet to be established whether the degree of CoQ10 uptake 
observed in these animal studies would be sufficient to restore 
cerebral ETC function.
The low bioavailability of some of the CoQ10 formulations 
used in these trials together with their low treatment doses or 
short durations may have contributed to the ambiguity in the 
results of the clinical trials (Table 1) [80,84,85]. CoQ10 doses 
typically in the range of 5–50 mg/kg/day are recommended in 
the treatment of patients with primary COQ10 deficiency and 
soluble forms are recommended instead of tablet forms, due 
to their higher bioavailability [86]. At present, however, there 
is no consensus on what dosage of CoQ10 is appropriate to 
administer to patients with other forms of ETC dysfunction. 
However, a dosage of at least 5 mg/kg/day is suggested [87]. 
Importantly, there is evidence of secondary CoQ10 deficiency 
associated with patients with ETC disorders, linked to 
a mutation in a gene not specifically involved in the CoQ10 
biosynthetic pathway; in some cases, these patients have been 
shown to be more responsive to CoQ10 therapy and have 
shown significant clinical improvement post CoQ10 supple-
mentation [88]. Moreover, this demonstrates the importance 
of determining the CoQ10 status prior to treatment, in order to 
identify any subgroups of patients with ETC disorders who 
may be more responsive to therapy [89]. It should also be 
noted that additionally to its supposed ability to improve 
electron transport in the ETC, the therapeutic efficacy asso-
ciated with CoQ10 in the treatment of mitochondrial disease 
may also be the result of its potent lipid soluble antioxidant 
capacity [78].
Table 1. Summary of the current clinical trials which have assessed the ther-
apeutic efficacy of CoQ10 in the treatment of ETC disorders. Abbreviations: 
MERRF: mitochondrial encephalopathy and ragged red fibers, MELAS: myoclonic 
epilepsy and lactic acidosis, CPEO: chronic progressive external ophthalmople-
gia, KSS: Kearns Sayre syndrome, NARP: Neuropathy, ataxia, and retinitis pig-
mentosa. Clinical trials which have assessed the efficacy of CoQ10 in the 
treatment of ETC disorders.
Study Possible flaws in study
1. In the study by Bresolin, et al. [92] 
44 mitochondrial patients 
(CPEO, KSS and MERRF) were 
treated CoQ10 
(2 mg/kg/day) for 6 months. 
54% of patients following 
CoQ10 treatment were found to 
have a 35% decrease in plasma 
lactate levels post exercise. 
These were deemed 
•responders however following 
a further 3 months of Colo 
treatment no differences were 
found between the 
•responders’ and the placebo 
group.
In the study, serum CoQ10 levels 
were reported as: 0.93 nmol/L 
(pre CoQ10 supplementation) 
and 1.33 nmol/L (post CoQ10 
supplementation). The general 
serum/plasma ref range is 
reported as: 0.48–1.8 PM 
[13,931. 
The level of CoQ10 only 
increased by approximately 
1.4-fold following CoQ10 
supplementation. Possibly due 
to the poor bioavailability of 
the COQ10 formulation used. 
Low dosage of CoQ10 used 
(2 mg/kg/day).
2. In the study by Chen, et al. [94] 
patients with mitochondrial 
encephalomyopathies (M ERRF, 
MELAS, CPEO) were treated 
with CoQ10 (160 mg/day) for 
3 months. A significant 
improvement in the global 
M RC score which is used for 
grading the muscle strength 
was noted in patients together 
with a nonsignificant decrease 
in plasma lactate levels post 
exercise. Patient serum CoQ10 
levels were decreased below 
control levels, 0.6–0.98 PM 
(patient); 0.57–1.83 gM (control 
range). Following 3 months of 
CoQ10 therapy the serum 
CoQ10 level of patients 
increased to 3.46 PM (3.5–5fold 
increase, approximately).
Low dosage of CoQ10 used 
(160 mg/day). 
No details oftype of CoQ10 
formulation were provided. 
Short duration trial (3 months). 
Patient fatigability was not 
significantly improved.
3. In the study by Glover, et al. [95] 
30 patients with MRC diseases 
(MELAS, CPEO, NARP, LHON) 
were treated with CoQ10 
(1200 mg/day) for 60 days. 
CoQ10 used in the study was 
a Q gel; Tishcon, New York. 
Following CoQ10 treatment, 
only a significant decrease in 
plasma lactate levels were 
observed post exercise in 
patients, no other clinical 
benefit noted.
The plasma CoQ10 status of the 
MRC patients showed no 
evidence of a CoQ10 
deficiency (mean plasma 
COQ10 status of patients: 
1.15 gM). Since these patients 
may not have an underlying 
CoQ10 deficiency, they may 
not be expected to show any 
clinical improvement following 
CoQ10 supplementation [96]. 
Short duration trial (60 days).
6 N. TURTON ET AL.
In light of their increased absorption, the use of both gel 
and oil-based formulations has been recommended over the 
use of conventional tablet formulations in patients with ETC 
disorders [90]. In a study by Martinefski, Samassa [91] it was 
reported that liquid emulsion improved the bioavailability of 
CoQ10 with respect to solid formulations. Currently, there is 
considerable debate as to whether formulations of ubiquinol 
rather than the ubiquinone form of CoQ10 have a better 
absorption from the gastrointestinal tract (GI). It has been 
reported that absorption of ubiquinol is three to four times 
higher than CoQ10 in the GI [91,92]. However, because during 
absorption in the GI CoQ10 undergoes reduction to ubiquinol, 
the suggested increased bioavailability of the ubiquinol for-
mulations may be due to the matrix in which the ubiquinol is 
held in rather than its redox state.
5. Conclusion
A number of studies have highlighted evidence of mitochon-
drial dysfunction in the pathophysiology of MS, PD and ETC 
disorders. Thus, is view of CoQ10’s significant role in the ETC, it 
may be deemed a potential therapeutic strategy in response 
to the aforementioned disorders. However, in some cases 
CoQ10 has demonstrated an inability to elicit significant neu-
rological outcome in MS, PD and ETC disorders and this has 
been discussed in the present review.
Although there is an abundance of evidence indicating the 
ability of CoQ10 to slow and even limit disease pathogenesis, 
there are certain diseases in which CoQ10 supplementation 
has only demonstrated a limited therapeutic benefit to 
patients. The factors that may contribute to the limited ther-
apeutic efficacy of CoQ10 are at present uncertain, but the 
paucity of hospital centers that are able to assess the endo-
genous CoQ10 status of patients and therefore indicate evi-
dence of an underlying CoQ10 deficiency should be taken into 
consideration. Furthermore, CoQ10 assessments are most often 
determined based on serum or plasma surrogates, which may 
not reflect endogenous levels. This may influence the ability of 
CoQ10 supplementation to impact the progression of the dis-
ease, because the severity of the CoQ10 deficiency may be 
masked by the use of inappropriate surrogates for endogen-
ous CoQ10 determination. In addition, a late diagnosis of 
a CoQ10 deficiency may result in irreversible disease progres-
sion and a limited response to CoQ10 supplementation. Other 
important factors to consider which may influence the clinical 
response to CoQ10 supplementation are the type of CoQ10 
formulation employed and the dosage used, as these factors 
will influence the absorption and bioavailability of CoQ10. 
Furthermore, the use of synthetic analogues of CoQ10 capable 
of passing through the BBB may also be a consideration.
In conclusion, it is currently uncertain why CoQ10 supple-
mentation may be ineffective in the treatment of the diseases 
discussed in this review and further studies may be required in 
order to establish appropriate quinone treatment protocols.
6. Expert opinion
In the present review, the inability of CoQ10 to augment sig-
nificant improvements in the pathophysiology and clinical 
outcome of three disorders of CNS was discussed. In some 
cases, CoQ10 treatment appeared to elicit little or no improve-
ment on disease pathophysiology; however, this in part may 
reflect the paucity of information currently available and the 
limited number of studies assessing the therapeutic efficacy of 
CoQ10 in the treatment of CNS disorders which is certainly the 
case for MS [93]. Furthermore, the inclusion of supplementary 
markers of disease severity should also be considered in clin-
ical studies such as, magnetic resonance imaging data to 
enable an accurate assessment of the effect of CoQ10 supple-
mentation on cerebral activity in these CNS disorders.
The aforementioned diseases are accompanied by evidence 
of mitochondrial dysfunction and oxidative stress [39,43]. 
Additionally, some studies have reported evidence of tangible 
improvements in mitochondrial functioning post treatment 
with CoQ10 [46]. Thus, in view of the important role CoQ10 
plays as an electron carrier in the ETC and as a potent anti-
oxidant, we cannot at present exclude the potential for CoQ10 
to elicit significant enhancement of mitochondrial functioning 
in the CNS disorders discussed in this review [15,45]. However, 
a lack of improved neurological outcome post treatment with 
CoQ10 may be attributable to the limited ability of CoQ10 to 
cross the BBB [94]. There is still uncertainty about the trans-
ports of CoQ10 across the BBB in humans and to date, no 
studies to date have yet assessed the transport of CoQ10 
across the human BBB. Animal studies, however, have shown 
a degree of CoQ10 transport across the BBB. In a study by 
Matthews, Yang [95] a 30% increase in cerebral cortex CoQ10 
and coenzyme Q9 (CoQ9; predominant ubiquinone species in 
rat) was reported following oral supplementation of 12-month 
-old Sprague-Dawley rats with CoQ10 (200 mg/kg) for 
2 months. Additionally, in a study by Smith, Matson [96] it 
was reported high-dose supplementation (1000–5000 mg/kg) 
led to a significant increase in CoQ10 concentrations in the 
brain of mice models. Yet, it is unclear whether this increase in 
CoQ10 status following supplementation would be sufficient to 
replenish an underlying cerebral CoQ10 deficiency. An in vitro 
study assessing the transport of CoQ10 across the BBB has 
reported that the uptake of CoQ10 via the Receptor for 
Advanced glycation end products (RAGE) and SR-B1 (scaven-
ger Receptor) correlates with an efflux via the low-density 
lipoprotein receptor (LDLR) transporters, demonstrating that 
CoQ10 transcytosis occurs in both directions, resulting in no 
‘net’ transport across the BBB [94]. In view of this, administra-
tion of LDLR inhibitors or the stimulation of the luminal activ-
ity of SR-B1 transporters in conjunction with CoQ10 
supplementation may be an appropriate method to enhance 
the CNS uptake of exogenous CoQ10. Alternatively, the short- 
chain analog of CoQ10, idebenone which has been reported to 
readily cross the BBB [97] should also be considered as an 
alternative means of targeting the ETC dysfunction and oxida-
tive stress associated with the CNS disorder discussed in this 
review. Idebenone administration has been reported to 
improve oxidative metabolism in patients with the CNS mito-
chondrial syndrome, MELAS [98]. Therefore, idebenone may 
be an appropriate alternative to CoQ10 in the treatment of MS, 
PD and ETC disorders, although it should be noted that this 
therapy may be disease dependent. Furthermore, idebenone 
treatment has been reported to induce oxidative stress in 
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in vitro studies and exacerbate disease presentation in 
a patient with a primary deficiency in CoQ10 biosynthesis 
and therefore caution should always be exercised before 
replacing CoQ10 with idebenone in therapeutic regime of 
patients [15].
Factors such as the time of disease diagnosis, dosage, 
administration, and duration of CoQ10 therapy may have 
a significant influence on the efficacy of this treatment. For 
example, the studies discussed in this review generally lacked 
long-term follow-up reports that exceeded 3-months to iden-
tify significant changes with CoQ10 intervention over longer 
periods of time [58]. Thus, we cannot at present exclude the 
possibility that there may be possible long-term beneficial 
effects associated with CoQ10 therapy. In addition, the studies 
discussed used a range of CoQ10 dosages; however, at present 
there is no consensus on the appropriate dosage of CoQ10 
required to elicit significant clinical benefit to the patient. 
Doses as high as 2400 mg/day are being administered in the 
treatment of PD [99]. However, doses exceeding this level may 
result in a block of GI absorption and split dosing is recom-
mended for patient administration [100,101]. Additionally, pri-
mary CoQ10 deficiencies if diagnosed at the early stage of the 
disease have been widely reported to be responsive to CoQ10 
supplementation with accompanying clinical improvement 
being observed [102]. However, the stage of the disease may 
be important when CoQ10 supplementation is initiated, as if 
this occurs after irreversible organ damage has occurred no 
therapeutic efficacy may be elicited even in cases of primary 
CoQ10 deficiency [10].
It should also be noted that evidence of an underlying deficit 
in CoQ10 status has been observed among some patients with 
ETC disorders and PD [103,104]. Thus, it would be anticipated 
that these patients may be more responsive to CoQ10 supple-
mentation, and this should be considered upon administration. 
In view of this, the level of CoQ10 in patients should be assessed 
prior to administration to determine which patients may benefit 
from CoQ10 intervention. Interestingly, a deficit in serum COQ10 
levels was not reported in MS patients [105]. This may justify 
why MS patients in some cases do not respond to this therapy 
[7]. In addition to this, the stage of the disease progression when 
CoQ10 is administered may be of importance, as patients with 
early-stage disease (prior to irreversible CNS damage) may be 
more responsive to CoQ10.
Other dietary preferences and supplementation taken in 
response to MS, PD and ETC disorders may influence the 
absorption of CoQ10. For example, high-dose vitamin 
E administration may compete with CoQ10 for GI absorption 
[106], resulting in lower plasma CoQ10 levels and these factors 
should all be taken into consideration prior to supplementing 
CoQ10 in these disorders. The beneficial effect of CoQ10 on 
these disorders although not clearly demonstrated cannot at 
present be excluded at this juncture. Further studies are 
required addressing the points raised in this section before 
the therapeutic potential of CoQ10 in the treatment of MS, PD 
and ETC disorders can be finally discounted.
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